Rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam

Therapeutic Drug Monitoring

Volumn 28, Issue 3, 2006, Pages 299-302

  Ujiie, Yukihiro ^a   Fukasawa, Takashi ^a   Yasui Furukori, Norio ^b   Suzuki, Akihito ^a   Tateishi, Tomonori ^b   Otani, Koichi ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Brotizolam; CYP3A4; Induction; Metabolism; Rifampicin

Indexed keywords

BROTIZOLAM; PLACEBO; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FUNCTION TEST; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE;

ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; AZEPINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; RIFAMPIN;

EID: 33748193400     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000200010.33430.0e     Document Type: Article

References (23)

1. Langley MS, Clissold SP. Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. Drugs. 1988;35:104-122.
2. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokin Biopharm. 1996;24:475-490.
3. Yasui N, Otani K, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther. 1996;59:514-519.
4. Yasui N, Kondo T, Otani K, et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berlin). 1998;139:269-273.
5. Furukori H, Otani K, Yasui N, et al. Effect of carbamazepine on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Neuropsychopharmacology. 1998;18:364-369.
6. Araki K, Yasui-Furukori N, Fukasawa T, et al. Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol. 2004;60:427-430.
7. Kondo S, Fukasawa T, Yasui-Furukori N, et al. Induction of the metabolism of etizolam by carbamazepine in humans. Eur J Clin Pharmacol. 2005;61:185-188.
8. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993;53:298-305.
9. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther. 1994;56:601-607.
10. Senda C, Kishimoto W, Sakai K, et al. Identification of human cytochrome P450 isoforms involved in the metabolism of brotizolam. Xenobiotica. 1997;27:913-922.
11. Tokairin T, Fukasawa T, Yasui-Furukori N, et al. Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. Br J Clin Pharmacol. 2005;60:172-175.
12. Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin. Clinical relevance. Clin Pharmacokinet. 2003;42:819-850.
13. Schmider J, Brockmoller J, Arold G, et al. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics. 1999;9:725-734.
14. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996;59:7-13.
15. Villikka K, Kivisto KT, Backman JT, et al. Triazolam is ineffective in patients taking rifampin. Clin Phermacol Ther. 1997;61:8-14.
16. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York, NY: Harcourt Brace Jovanovich; 1981.
17. Hoddes E, Zarcone V, Smythe H, et al. Quantification of sleepiness: a new approach. Psychophysiology. 1973;10:431-436.
18. Hikida K, Inoue Y, Nouchi E, et al. Determination of etizolam in human serum or plasma using automated column-switching high-performance liquid chromatography. Jpn J Clin Chem. 1990;19:354-359.
19. Steinijans VW, Hartmann M, Huber R, et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol. 1991;29:323-328.
20. Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet. 1989;16:337-364.
21. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam: therapeutic implications. Clin Pharmacokinet. 1993;24:453-471.
22. Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia. 1996;37:253-257.
23. Ballenger JC. Benzodiazepines. In: Schatzberg AF, Nemeroff CB, eds. Text Book of Psychopharmacology. 2nd edn. Washington, DC: American Psychiatric Press; 1998:271-286.